A pproximately 250,000 Americans suffer out-of-hospital cardiac arrests each year. 1, 2 Available evidence supports the use of implantable cardioverter defibrillators (ICDs) in individuals at highest risk for cardiac arrest (e.g., those with an ejection fraction of 30%) because their risk of cardiac arrest is 5% to 10% per year. [3] [4] [5] [6] However, approximately 70% of outof-hospital cardiac arrests occur among individuals at increased risk for sudden cardiac death (SCD) but who lack sufficient risk to warrant a prophylactic ICD. 1, [7] [8] [9] [10] In the absence of an ICD, survival of out-of-hospital cardiac arrest depends upon a rapid response by emergency medical services (EMS) to deliver defibrillation. While cardiac arrest survival rates of 25% have been reported, prolonged EMS response times and survival rates of 3% to 5% are common. [11] [12] [13] [14] In an effort to reduce the time-to-defibrillation interval and improve cardiac arrest survival, the public health system has increasingly turned to a strategy of public access defibrillation (PAD) to augment EMS. 15 The strategy of PAD is predicated upon the idea that automated external defibrillators (AEDs) should be placed in densely populated public locations where cardiac arrests are likely to occur. 16 A recently published study demonstrated that PAD can increase cardiac arrest survival, 17 but PAD is hampered by at least 2 important constraints 18, 19 . First, there are an infinite number of public locations where cardiac arrests may occur and AEDs can be deployed; second, PAD is ineffective for the 50% to 70% of out-of-hospital cardiac arrests that occur in private homes. 7, 15, [20] [21] [22] One potential solution to the problem of in-home cardiac arrests is to provide individuals at increased risk of SCD with personal AEDs for in-home use. While the idea of home defibrillators has been contemplated for many years, only recently have improvements in technology made in-home AEDs a viable option. 15, 23, 24 The Federal Drug Administration (FDA) responded to these improvements by approving AEDs for in-home use with a prescription in 2002 and is currently considering over-thecounter availability. 25, 26 However, the relationship between an individual's risk of SCD and the cost-effectiveness of in-home AED deployment relative to EMS is unknown. Accordingly, we developed a decision analytic model to evaluate the clinical and economic consequences of in-home AED deployment for individuals at increased risk of SCD in an effort to clarify the relationship between an individual's risk of SCD and the cost-effectiveness of an in-home AED.
METHODS

Literature Review
MEDLINE was used to search the 1966-2003 medical literature using the terms heart arrest, emergency medical services, and public access defibrillation, as were abstracts of major scientific meetings from 2000 to 2003. Bibliographies of selected review articles were scanned to identify additional articles.
Relevant articles were abstracted by one of the authors (P.C.) to obtain the values for the model. In cases where multiple publications estimating a particular input were available, we assessed the methodology of each study and used the estimate from the study deemed to be the most methodologically sound. If no single study was superior, we took the mean of the estimates provided by the available studies and used broad confidence intervals to incorporate the range of available estimates into sensitivity analysis.
Decision Analytic Model
We constructed a Markov decision model using the societal perspective to evaluate the lifetime clinical and economic impact of 2 alternative strategies in a cohort of adults 60 years of age ( Fig. 1 ): strategy 1: individuals suffering an in-home cardiac arrest initially received cardiopulmonary resuscitation (CPR) followed by care administered by EMS equipped with AEDs (EMS-D); strategy 2: individuals suffering an in-home cardiac arrest were initially treated with a home AED followed by care administered by EMS-D (AED). The two strategies differed only in the initial availability of an AED and its impact on cardiac arrest survival and costs. All probabilities for model inputs are shown in Table  1 . Patient Population, Probability of Cardiac Arrest, and AED Use While the risk of SCD among an unselected population of American adults is 0.4% per year, the probability of cardiac arrest among adults with multiple SCD risk factors ranges from 2% to 6% per year depending upon the precise population. 1, 3, 5, 8, 9, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] We evaluated the cost-effectiveness of inhome AEDs among 4 cohorts of adults at progressively increasing risk of SCD: 1) all adults (initial probability of SCD at age 60 of 0.4%); 2) adults with multiple SCD risk factors such as hypertension or left ventricular hypertrophy (initial probability 2%); 3) adults with previous myocardial infarction (initial probability 4%); and 4) adults with ischemic cardiomyopathy and an ejection fraction 30%, but unable/unwilling to receive an ICD (initial probability 6%). Individuals in each cohort were considered to be at risk for both SCD and death from other causes on an annual basis. The initial risk of both SCD and overall mortality in each cohort were derived from the medical literature and assumed to increase in subsequent years based upon life-table estimates. 27, 38 Available evidence suggests that 50% to 70% of all out-ofhospital arrests occur at home and that at least 50% are witnessed. 15, [20] [21] [22] 39 However, even if a cardiac arrest occurs at home, is witnessed, and an AED is available, it is likely that the device will not always be used. In the base-case, it was assumed that 50% of all arrests occurred at home and that 40% of these arrests were witnessed and treated with the available in-home AED. These assumptions were evaluated in sensitivity analyses. It was assumed that an in-home AED was used exclusively for arrests that occurred in the home of the individual for whom the device was prescribed and that the only person at FIGURE 1. Decision analytic model for strategy 2.
risk of suffering an in-home cardiac arrest was the individual for whom the AED was prescribed. It was also assumed that all individuals purchasing an in-home AED lived with at least one other person capable of using the device.
Costs
Costs included in the model are shown in Table 1 . Individuals in each of the 4 cohorts accrued annual medical costs based upon values in the published literature. [40] [41] [42] [43] [44] The cost of an inhome AED was $2,000; 45 AED maintenance costs were also included in the model. 45, 46 We assumed that for each AED purchased, two individuals would undergo CPR and AED training on a biennial basis (the individual ''at-risk'' and one cohabitant). Additional costs were included to account for the time required for training. 47 Previous studies have demonstrated that the cost of hospitalization for cardiac arrest victims varies, depending upon whether an individual dies in the hospital or survives to discharge. 46, [48] [49] [50] [51] Hospitalization costs among cardiac arrest survivors accounted for the expectation that most would receive an ICD. Future medical costs incurred by cardiac arrest survivors were included in the model and accounted for the likelihood that a proportion of survivors would require long-term care. 46, 48, 49 Historical costs were adjusted to 2004 dollars using an inflation rate of 2.5% to reflect inflation in the consumer price index between 1999 and 2002. 52 Future costs and benefits were discounted at 3% in accordance with accepted guidelines. 53 
Effectiveness of Strategy 1
In the absence of an in-home AED, individuals suffering an arrest at home would be treated by EMS equipped with AEDs (EMS-D). While survival rates of 25% have been reported with optimized EMS-D, survival rates of 3% to 5% are common in congested urban and remote rural areas. [11] [12] [13] [14] [54] [55] [56] ; this variation in survival reflects the fact that cardiac arrest survival falls by approximately 10% per-minute delay in defibrillation. 57 In the base-case, 15% of in-home cardiac arrest victims were assumed to survive to hospital discharge based upon survival rates with an optimized EMS-D system and a time-to-defibrillation interval of 10 minutes. 58, 59 This assumption was deliberately optimistic for EMS-D and it is likely that many cardiac arrest victims experience a time-to-defibrillation interval of 15 minutes or more, thus resulting in cardiac arrest survival rates of 10% or less. Sensitivity analysis was used to assess the impact of varying time-to-defibrillation intervals and corresponding changes in arrest survival rates on overall cost-effectiveness.
Effectiveness of Strategy 2
The benefit of in-home AEDs is directly related to any increase in survival that they confer (strategy 2) relative to EMS-Dbased care (strategy 1). No published studies have examined the impact of in-home AEDs on cardiac arrest survival. However, studies examining the impact of AED deployment in public locations (PAD) on cardiac arrest survival are highly applicable. [17] [18] [19] Based upon these studies and an average time-to-defibrillation interval of 5 minutes, cardiac arrest survival with an in-home AED was estimated to be 30% in the base-case.
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Life Gained Among Arrest Survivors 67 and Granja et al. 65 Utility scores for the moderately and severely impaired survivors were estimated based upon published data from stroke survivors with similar levels of functional impairment. 68 
Sensitivity Analysis
Because of uncertainty regarding the precise values of many of the model inputs, a series of 3 sensitivity analyses were performed. First, one-way sensitivity analyses were performed across the range of values available for each of the model inputs. Next, two-way sensitivity analyses were conducted using combinations of model variables to further assess the impact of uncertainty on our findings. Finally, Monte Carlo simulation was conducted to allow all variables to vary simultaneously in further effort to assess the robustness of our findings. For this analysis, variables related to costs and survival were assigned log-normal distributions, while all others were given normal distributions.
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RESULTS
Cost-effectiveness of In-home AED
The cost-effectiveness of the 4 alternative strategies for inhome AED deployment is shown in Table 2 . Providing in-home FIGURE 2. Two-way sensitivity analysis involving probability of SCD and life expectancy for arrest survivors.
AEDs to all adults 60 years of age (0.4% probability of SCD) costs an incremental $5,175 per person and results in a gain of 0.024 quality-adjusted life-year (QALYs), leading to a cost per QALY gained of $216,000. Limiting distribution of in-home AEDs to specific populations at increased risk of SCD results in improved cost-effectiveness ratios: individuals with multiple SCD risk factors (2% probability of SCD) cost $132,000 per QALY; individuals who had suffered a previous myocardial infarction (4% probability of SCD) cost $104,000 per QALY; and individuals with ischemic cardiomyopathy who were unable/unwilling to receive an ICD (6% probability of SCD) cost $88,000 per QALY.
One-way Sensitivity Analyses
Results of one-way sensitivity analyses for selected variables performed on 2 of the selected patient cohorts (multiple SCD risk factors and ischemic cardiomyopathy) are shown in Table  3 . The results were sensitive to the probability that the arrest occurred at home, the probability that the available AED was used, and the probability of suffering SCD, as demonstrated above. The cost-effectiveness of in-home AED deployment was also sensitive to changes in the relative benefit of AED deployment (strategy 2) compared to EMS-D care (strategy 1). For example, for individuals with multiple SCD risk factors, as the probability of survival to hospital discharge with EMS-D decreased from 29% to 3% (corresponding to a time-to-defibrillation delay increasing from 5 minutes to 20 minutes), the cost-effectiveness ratio for in-home AEDs decreased from $5,140,000 to $86,000 per QALY gained when compared with EMS-D. Likewise for individuals with multiple SCD risk factors, as the probability of arrest survival with an in-home AED increased from 20% to 50% (corresponding to a time-to-defibrillation delay decreasing from 7 minutes to 3 minutes), the cost per QALY gained decreased from $328,000 to $76,000. The cost-effectiveness of in-home AED deployment was relatively insensitive to variations in all cost parameters. Figure 2 illustrates a two-way sensitivity analysis involving the probability of an individual suffering SCD and the life expectancy of cardiac arrest survivors. Depending upon the population considered, the annual probability of SCD in a cohort 60 years of age may range from 0.4% (all adults) to 6% (adults with ischemic cardiomyopathy). In addition, while the basecase assumed that cardiac arrest survivors would live an additional 6 years, available evidence suggests that life expectancy may be as little as 3 years or as great as 9 years. Assuming life expectancy for cardiac arrest survivors of 9 and 6 years, the cost-effectiveness ratio crosses the $100,000/QALY threshold at annual probabilities of cardiac arrest of 2% and 4%, but never falls beneath the $50,000/ QALY threshold. Figure 3 illustrates the impact of a two-way sensitivity analysis involving the probability of an individual suffering SCD and the absolute reduction in the time-to-defibrillation interval afforded by an in-home AED compared to EMS-D care. In the base-case, it was assumed that cardiac arrest survival with EMS-D was 15% versus 30% with an in-home AED; this corresponds to a time-to-defibrillation interval of 10 minutes for EMS-D and 5 minutes for an in-home AED (a 5-minute ''time-savings'' with an in-home AED). If, however, the reduction in the time-to-defibrillation interval with an in-home AED is greater, the cost-effectiveness ratio becomes more favorable. For example, if the time savings with an in-home AED is 15 minutes (i.e., time-to-defibrillation interval of 20 minutes and survival of 3% with EMS-D vs time-to-defibrillation interval of 5 minutes and survival of 30% with AED) rather than 5 minutes, the cost per QALY gained for providing in-home AEDs to individuals with a 2% probability of SCD falls from $132,000 to $86,000.
Two-way Sensitivity Analyses
Multiway Sensitivity Analysis
Monte Carlo simulation conducted while holding the annual risk of cardiac arrest constant at 2% demonstrated a mean cost of $176,000 per QALY gained (standard deviation $5,800; median $159,000). The simulation demonstrated that the cost per QALY gained fell below $100,000 in 23% of all trials and below $50,000 in 4%. Monte Carlo simulation conducted while holding the annual risk of cardiac arrest constant at 4% revealed mean and median costs per QALY gained of $131,000 and $105,000, respectively; increasing the probability of cardiac arrest to 6% resulted in mean and median of $105,000 and $88,000. Alternatively, changing 3 of our base-case assumptions simultaneously: 1) increasing the probability that an in-home AED will be used from 40% to 60%; 2) decreasing the probability of cardiac arrest survival with EMS from 15% to 10%; and 3) increasing the probability of cardiac arrest survival with an in-home AED from 30% to 40% while holding the annual probability of cardiac arrest constant at 2% reduced the cost per QALY gained from $132,000 to $65,000. Maintaining these 3 changes and simultaneously increasing the annual probability of cardiac arrest to 4% and 6% resulted in costs per QALY gained of $56,000 and $50,000, respectively.
DISCUSSION
The current analysis suggests that the cost-effectiveness of inhome AED is intimately linked to an individual's risk of cardiac arrest. While purchase of in-home AEDs may be reasonable for adults with increased risk of SCD, providing in-home AEDs to all adults is expensive when compared to commonly accepted cost-effectiveness thresholds 70, 71 ; our findings also demonstrate that the cost-effectiveness of in-home defibrillators is particularly sensitive to the reduction in the time-to-defibrillation interval that an in-home AED provides relative to EMS-D-based care. Although the decision to recommend an inhome AED to an individual patient is complex, the results of our cost-effectiveness analysis suggest that several specific clinical factors (e.g., patient risk, distance/time from EMS care) should be considered prior to making such a decision. The fact that the cost-effectiveness of an in-home AED is sensitive to the probability of an individual suffering a cardiac arrest demonstrates that risk assessment is critical. While accurately predicting an individual's risk for SCD is currently difficult, it is possible to risk stratify individuals using widely available information such as age, cardiac risk factors, and history of coronary artery disease. The importance of an individual's risk also reinforces the importance of continued research to allow for more accurate individualized risk assessment. 8, 72 Also, our findings demonstrate the importance of considering the expected time-to-defibrillation interval at an individual's home. Individuals living in congested urban or remote rural areas are likely to experience prolonged delays to defibrillation and thus low survival rates in the absence of an in-home AED. Conversely, individuals living in close proximity to trained first responders are likely to experience shorter delays and receive less benefit from an in-home AED.
In discussing the current analysis, it is important to note the limitations of our work. We were deliberately conservative in all of our model estimates to avoid overestimating the effec-FIGURE 3. Two-way sensitivity analysis involving probability of SCD and the reduction in the time-to-defibrillation interval offered by in-home AEDs.
tiveness of in-home AEDs, but consequently may have underestimated the benefits offered by in-home AEDs. For example, our estimation of 15% survival of cardiac arrest with EMS-D was based upon an optimized program, but reported survival rates in most communities are 5% to 10%. We also assumed that an in-home AED would only benefit the individual for whom the device had been purchased. However, data are already emerging to suggest that in-home AEDs are likely to benefit individuals other than the person for whom the device was purchased. 73, 74 Modifying the model in the aforementioned ways would enhance the cost-effectiveness of in-home AEDs. In addition, the current analysis did not incorporate the fact that in-home AEDs could increase anxiety for both patients and family members, thereby worsening the cost-effectiveness of the intervention. However, such anxiety has not been previously demonstrated. Finally, our analysis did not capture potential complications resulting from in-home AED deployment, but this appears to be justified based upon the safety record of modern AEDs; the ongoing Home Use AED (HAT) trial will help to clarify the frequency of such complications.
In conclusion, in-home AEDs may be a reasonable investment for individuals at increased risk of SCD, but populationbased deployment to all adults 60 years of age is relatively expensive. However, modest modifications of our conservative base-case assumptions make population-based in-home defibrillators appear more cost-effective when compared to other home safety devices that are commonly purchased. FDA approval of over-the-counter AEDs will force patients and providers to explicitly assess the risk and value that in-home AEDs provide.
